Positional isomers and analogs of mazindol as potential inhibitors of the cocaine binding site on the dopamine transporter site

Medicinal Chemistry Research

Volumn 8, Issue 1-2, 1998, Pages 77-90

  Houlihan, William J ^a   Boja, John W ^b,c   Kopajtic, Theresa A ^b   Kuhar, Michael J ^b,d   Degrado, Sylvia J ^a   Toledo, Leonel ^a  

^a DREW UNIVERSITY   (United States)

^b NIDA Addiction Research Center   (United States)

^c NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

^d EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3BETA (4 FLUOROPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; COCAINE; DOPAMINE TRANSPORTER; MAZINDOL;

ANIMAL TISSUE; ARTICLE; BINDING COMPETITION; CORPUS STRIATUM; DOPAMINE UPTAKE; DRUG BINDING SITE; DRUG PROTEIN BINDING; DRUG SYNTHESIS; ISOMER; MALE; NONHUMAN; RAT;

EID: 0031832172     PISSN: 10542523     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. (a) Altman, J.; Everitt, B.J.; Gluautier, S.; Markov, A.; Nutt, D.; Oretti, R.; Phillips, G.D.; Robbins, T.W. Psychopharmacology 1996, 125, 285-345.
2. (b) Zafar, N.; Vaz, A.; Carlson, R.W. Hospital Practice 1997, 167-181.
3. Boja, J.W.; Vaughan, R.; Patel, A.; Shaya, E.K.; Kuhar, M. J. In The Dopamine Receptors and Transporters; Niznik, H.B., Ed.; Marcel Dekker, Inc.; New York, 1994; pp 611-644.
4. Giros, B.; Jaber, M.; Jones, S.R.; Wightman, R.M. Caron, M.G. Nature 1996, 379, 606-612.
5. Volkow, N.D.; Wang, G.-J.; Fischman, M.W.; Foltin, R.W.; Fowler, J.S.; Abumrad, N.N.; Vitkun, S.; Logan, J.; Gatley, S.J.; Pappas, N.; Hitzemann, R.; Shea, C.E. Nature 1997, 386, 827-830.
6. (a) Leshner, A.I. Hospital Practice 1996, 47-59.
7. (b) Rothman, R.B. Life Sci. 1990, 46, 17-21.
8. (c) Carroll, F.I.; Lewis, A.H.; Biswas, J. Chemical Pharmaceut. News 1994, 1, 11-17.
9. (d) Carroll, F.I.; Lewin, A.H.; Kuhar, M.J. In Neurotransmitter Transporters: Structure, Function and Regulation; Reith, M.E.A., Ed.; Humana Press, Inc.: Totowa, NJ, 1996; pp. 263-295.
10. (e) For other treatment approaches, see: Landry, D.W. Sci. Amer. 1997, February, 42-45.
11. (a) Javitch, J.A.; Blaustein, R.O.; Snyder, S.H. Mol. Pharmacol, 1984, 26, 35-44.
12. (b) Giros, B.; Caron, M.G. Trends Pharmacol. Sci. 1993, 14, 43-44.
13. (c) Kozikowski, A.P.; Liang, L.; Tanaka, J.; Bergmann, J.S.; Johnson, K.M. Med. Chem. Res. 1991, 1, 312-321.
14. (a) Chait, L.D.; Uhlenhuth, E.H.; Johanson, C.E. J. Pharmacol. Exp. Ther. 1987, 242, 777-783.
15. (b) Chait, L.D.; Uhlenhuth, E.H.; Johanson, C.E. Pharmacol. Biochem. Behavior 1986, 24, 1665-1672.
16. (c) DeFelice, E.A.; Bronstein, S.; Cohen, A. Curr. Res. Ther. 1969, 11, 256-262.
17. (d) Gotetam, K.G.; Gunne, L.M. Br. J. Addict. 1972, 67, 39-44.
18. (e) Gotetam, K.G. Curr. Med. Res. Opin. 1979, 6, 125-134.
19. (f) Chambers, C.D. In Amphetamine Use, Misuse and Abuse: Proceedings of the National Amphetamine Conference, 1978; Smith, D.E., Wesson, D.R., Buxton, M.E., Seymour, R.B., Ungerledider, J.T., Morgan, J. P. Mandell, A.J., Jara, G., Eds.; G.K. Hall and Co.: Boston, MA, 1979; pp. 92-103.
20. (a) Berger, P.; Gawin, F.; Kosten, T.R. Lancet 1989, No. 2, 283.
21. (b) Diakogiannis, I.A.; Steinberg, M.; Kosten, T.R. In Problems of Drug Dependence 1990; Proceeding of the 52nd Annual Scientific Meeting of the Committee on Problems of Drug Dependence, Inc.; Harris, L., Ed.; National Institute on Drug Abuse: Rockville, MD, 1990; p 514.
22. (c) Preston, K.L.; Sullivan, J.T.; Berger, P.; Bigelow, G.E. J. Pharmacol. Exp. Ther. 1993, 267, 296-307.
23. Stine, S.M.; Krystal, J.H.; Kosten, T.R.; Charney, D.S. Drug and Alcohol Dependence 1995, 39, 245-252.
24. Margolin, A.; Avants, S.K.; Kosten, T.R. Am. J. Drug Alcohol Abuse 1995, 21, 469-481.
25. Houlihan, W.J.; Boja, J.W.; Parrino, V.A.; Kopajtic, T.A.; Kuhar, M.J. J. Med. Chem. 1996, 39, 4935-4941.
26. Barcza, S.; Houlihan, W.J. J. Pharm. Sci. 1975, 64, 829-831.
27. Smith, W.J.; Schmitting, E.A.; Sawyer, J.S. Abstr. 1994, 208th National ACS Meeting, #65.